Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change

ConclusionsWe have studied populations of patients with CF receiving dornase alfa who were switched between regimens to characterize clinical course. Our results suggest that the most common clinical attribute associated with switching from QD to BID dornase alfa was a marked deterioration in stability characterized by increased incidence and frequency of pulmonary exacerbation. For this population, deterioration in lung function did not appear to be a driver for this switch. In contrast, patients receiving BID dornase alfa who were ultimately switched to QD appeared to be clinically stable, on average, suggesting that treatment burden and cost may have been drivers of the decision to switch regimens.
Source: Pediatric Pulmonology - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLE: CYSTIC FIBROSIS Source Type: research